Gapping up
In reaction to strong earnings/guidance: TIF +6.4%, EHIC +5.1%, TIVO +4.1%, NMBL +2%, MOV +1.7%, DSW +0.9%
M&A news: HRL +4.9% (to acquire prepared meats provider Applegate, for $775 mln; with expected EPS accretion of $0.07-0.08/share in 2016), TIVO +4.7% (acquired Cubiware, a provider of cost-effective software solutions for emerging market Pay-TV operators; co also reported earnings), NOK +1.5% (has acquired Eden Rock Communications, a provider of Self Organizing Network solutions)
Other news: EOX +76% (co elected not to proceed with public offering of common stock; reiterates previously announced 2015 guidance for CapEx of $65 mln), XBIT +18.2% (announced it has successfully isolated and cloned an anti-Ebola product candidate using its True Human antibody discovery platform), RSYS +18.1% (announced follow-on order of ~$11 mln for MediaEngine product from a large Asian carrier), NSPH +11.3% (Perella Weinberg Partners Capital Management disclosed 9.3% passive stake in 13G filing; SWK Holdings Corporation disclosed 6.4% passive stake in 13G filing), RTRX +11.1% (agrees to sell priority review voucher to Sanofi (SNY)), OXGN +10.9% (announced issuance of a U.S. patent for OXi4503 in acute myeloid leukemia),CBLI +10.8% (attributed to positive story ahead of the co's entolimod presentation on 5/30 at ASCO Conference), GALE +7% (announces two abstract publications at the ASCO 2015 Annual Meeting), JMEI +5.2% (to host a conference call at 08:30 AM ET today to discuss changes in import tariffs on cross border beauty product sales), NBG +4% (cont volatility surrounding Greece default), ALU +3.4% (in sympathy with NOK), HA +3.3% (to replace OZRK in the S&P SmallCap 600), PLUG +3.1% (announces a master sales agreement with a large footwear manufacturer in North America), FXCM +2.5% (cont strength), ZSPH +2.3% (submitted an NDA to the U.S. FDA for ZS-9, to treat Hyperkalemia), YELP +1.2% (Eminence Capital discloses 5.1% passive stake in 13G filing), ABBV +0.9% (discloses entry into an accelerated share repurchase agreement with Morgan Stanley to repurchase $5 bln of common stock)
Analyst comments: OPXA +31.6% (initiated with a Buy at Maxim Group; tgt $5), FTR +5.7% (upgraded to Overweight from Underweight at Morgan Stanley), FRO +3.2% (upgraded to Equal-Weight from Underweight at Morgan Stanley), HDP +1.9% (initiated with an Outperform at Oppenheimer ), RAD +1.9% (initiated with a Buy at Mizuho), CX +1.5% (upgraded to Buy from Neutral at Longbow), MPC +1.3% (upgraded to Outperform from Perform at Oppenheimer), ULTA +1% (initiated with a Buy at Buckingham Research), DFT +0.9% (upgraded to Outperform from Neutral at Macquarie)